PDCD1 and non-small cell lung carcinoma: Clinical studies have validated the therapeutic benefit of PD-1/PD-L1 blockade in malignancies such as metastatic melanoma, NSCLC, renal cell carcinoma, bladder, and head and neck cancers (137, 138).